What Is the Life Expectancy of Someone With Stiff Person Syndrome?

There is no single life expectancy figure for stiff person syndrome (SPS) because the condition varies dramatically from person to person, but population data confirms that mortality is significantly elevated. A nationwide Danish study found that roughly one in five people diagnosed with SPS died within five years, and the risk of death was about five times higher than in the general population over that period.¹ That said, many people live for decades with the disease, particularly when it is caught early and treated aggressively. The range of outcomes depends on the specific variant, how quickly a diagnosis is made, how well the person responds to treatment, and what other conditions they carry alongside SPS.

What the Mortality Numbers Actually Show

The best population-level survival data comes from a Danish registry study that tracked everyone diagnosed with SPS in Denmark and compared them to matched members of the general population. Two-year mortality was about 17% in the SPS group versus less than 2% in the comparison group. At five years, roughly 22% of people with SPS had died, compared with about 5% of the general population. At ten years, the figure reached about 28% versus 13%.¹ After adjusting for age, sex, and other health conditions, the risk of death was nearly seven times higher in the first two years after diagnosis, about five times higher over five years, and four times higher over a decade.

These numbers deserve some context. SPS is extremely rare, so even a national registry captures a relatively small cohort. Confidence intervals around those mortality estimates are wide, meaning the true rates could be somewhat higher or lower. The data also reflects a mixture of SPS subtypes and treatment histories, so an individual’s prognosis can look quite different from the average. Still, the pattern is clear: SPS carries a meaningful mortality risk, and that risk is front-loaded, highest in the first few years after diagnosis.

How SPS Can Be Fatal

SPS does not usually kill through a single predictable pathway the way some progressive neurological diseases do. Instead, several distinct mechanisms can prove fatal, and some of them strike without much warning.

The most alarming is sudden death tied to autonomic crises. SPS can trigger episodes of severe autonomic instability: dangerously high blood pressure, rapid heart rate, spiking body temperature, and profuse sweating, all driven by uncontrolled spasms. Case reports describe patients dying suddenly during such episodes despite otherwise stable disease courses.² One published case involved a man in his thirties who developed whole-body spasms followed by severe respiratory failure and cardiac arrest during an attempted removal of a breathing tube.³

Respiratory failure is another serious threat. When stiffness and spasms involve the muscles of the chest wall and diaphragm, breathing can become compromised. Some patients experience recurrent bouts of respiratory failure that require mechanical ventilation and intensive care.⁴ In at least one documented case, a patient’s respiratory muscles became so rigid that a ventilator and continuous ICU monitoring were needed until immunotherapy kicked in.⁵ Interruptions in treatment, missed medication doses, or concurrent infections can all trigger these episodes.

Falls and fractures represent a slower but grinding source of danger. Severe stiffness, sudden unpredictable spasms, and poor balance combine to cause frequent falls. In roughly two-thirds of cases, daily activities become difficult. Vigorous spasms can occasionally cause fractures or joint dislocations even without any external trauma.⁶ For older patients in particular, a hip fracture can set off a cascade of complications.

The Variant Matters Enormously

SPS is not a single disease but a spectrum, and where you fall on that spectrum has a huge effect on prognosis. The classic form, marked by trunk and limb stiffness with episodic spasms, is the most common and generally the most treatable. Partial or focal variants, which affect only one limb or region, tend to follow milder courses.

At the severe end sits progressive encephalomyelitis with rigidity and myoclonus, known as PERM. This variant involves the brainstem and spinal cord more extensively and progresses faster. In a study pooling 41 PERM patients with glycine receptor antibodies, 11 died, with 8 of those deaths directly caused by PERM complications. The functional impairment at its worst was severe across the board. On the positive side, among the patients who survived more than six months, relapses were common but consistently responded to immunotherapy, and about 70% of survivors had a good functional outcome at last follow-up.⁷ Older age and needing intensive care were independent predictors of worse outcomes. A separate case report described a 75-year-old PERM patient who deteriorated rapidly and died just 10 months after symptom onset despite aggressive immunotherapy and continuous intensive care.⁸

The takeaway is that lumping all SPS variants together creates a misleading picture. A person with classic SPS who responds well to treatment could live for many years with manageable symptoms, while someone with PERM faces a rockier path, especially if they are older at onset.

Why Diagnostic Delay Changes the Prognosis

One of the most frustrating aspects of SPS is how long it takes to get diagnosed, and that delay itself worsens outcomes. Diagnostic delay is strongly associated with irreversible disability.⁹ When the condition goes untreated or undertreated because of a late diagnosis, it tends to progress to a point where even good therapy cannot fully reverse the damage.¹⁰

The delays are often substantial. SPS symptoms, particularly stiffness, gait problems, and pain, overlap with many more common conditions. Patients are frequently misdiagnosed with anxiety disorders, conversion disorder, or other psychiatric conditions before anyone considers SPS. A systematic review found that diagnostic delays were often driven by the misattribution of symptoms as being purely psychiatric.¹¹ One published case documented a patient whose lower limb stiffness and gait problems were labeled conversion disorder for a full year before SPS was recognized. Once the correct diagnosis was made and immunotherapy started, the patient improved significantly.¹²

A small study of late-onset SPS, where symptoms began later in life, illustrated the speed of decline without timely intervention. Within about three years of symptom onset, most patients had serious gait problems and frequent falls, and nearly all needed a walking device. Two patients ended up in care facilities, and two others died.¹³ These outcomes likely reflect the combined effects of older age and delayed treatment.

Treatment and How It Shapes Survival

SPS treatment works on two tracks: controlling symptoms and targeting the underlying immune attack. Both matter for long-term survival, though neither is curative.

For symptom control, drugs that boost the brain chemical GABA are the first line. Diazepam is the standard, sometimes alongside baclofen. These medications reduce stiffness and the frequency of spasms, and most patients respond to them.¹⁴ The problem is the doses needed. Patients often require amounts far above what is typical for other conditions, sometimes up to 60 mg of diazepam daily. At those levels, sedation, drowsiness, and the risk of respiratory depression become real concerns, and long-term use creates dependence.¹⁵ Missing doses can trigger rebound spasms severe enough to land someone in the ICU, as documented in cases of respiratory failure precipitated by treatment interruptions.⁴

On the immune side, intravenous immunoglobulin (IVIg) is the best-studied therapy. A randomized controlled trial published in the New England Journal of Medicine showed that IVIg significantly reduced stiffness and hypersensitivity to stimuli. Eleven patients who received it became able to walk more easily or without assistance, fell less often, and could return to household or work tasks. The benefits lasted anywhere from six weeks to a year.¹⁶ In a longer-term maintenance study, about two-thirds of patients showed meaningful clinical improvement over a median period of roughly three and a half years. Some patients who had been wheelchair-bound regained the ability to walk without assistance.¹⁷

One complicating factor: antibody levels in the blood do not reliably predict how sick someone is or how they will respond to treatment. Some patients with very high antibody titers have mild disease, while others with low titers are severely affected. Serial measurements over time did not track with clinical ups and downs either.¹⁸ This means there is no simple blood test to predict who will do well and who will not.

When First-Line Treatment Fails

A sizable minority of SPS patients do not respond adequately to IVIg and standard symptom-control drugs. For these refractory cases, the options become more experimental and the evidence thinner.

Rituximab, a drug that depletes certain immune cells, has been tried extensively. A systematic review found that most treated patients showed significant clinical improvement, though only a small proportion achieved complete remission.¹⁹ However, the largest controlled trial of rituximab in SPS found no statistically significant difference between the drug and placebo. The researchers suggested this could be due to a strong placebo effect, the difficulty of measuring stiffness objectively, or the possibility that rituximab helps only a small subset of patients.²⁰ The disconnect between the uncontrolled case reports showing benefit and the controlled trial showing none is one of the more vexing puzzles in SPS research.

Autologous hematopoietic stem cell transplantation, which essentially reboots the immune system using a patient’s own stem cells, has been tried in a small clinical trial. There was no treatment-related mortality. About three-quarters of participants responded, and nearly half of those responders stayed in remission for an average of three and a half years. About a quarter of patients did not respond at all, and one participant died of disease progression a year after the transplant.²¹ A separate case report documented sustained improvement in a patient with glycine receptor antibody-positive SPS who underwent the same procedure.²² Stem cell transplantation is aggressive and carries its own risks, but for people who have failed everything else, it represents one of the few avenues with the potential for sustained remission.

The Burden of Autoimmune Comorbidities

SPS rarely travels alone. A meta-analysis found that about half of people with SPS spectrum disorders also have at least one other autoimmune condition.²³ The most common overlap is with diabetes, affecting roughly 29% of patients, followed by autoimmune thyroid disease at about 25%. Pernicious anemia, myasthenia gravis, vitiligo, and celiac disease also appear at rates far above what is expected in the general population.

These comorbidities matter for survival in a few ways. Type 1 diabetes adds its own set of complications: cardiovascular disease, kidney damage, and episodes of dangerous blood sugar levels. Thyroid disease, if poorly controlled, can worsen fatigue and muscle symptoms. The presence of additional autoimmune conditions was more common in patients who tested positive for GAD65 antibodies, showing up in about 64% of that group compared with about 34% of GAD65-negative patients.²³ The PERM variant had the highest rate of autoimmune comorbidities at nearly 80%.

For patients managing SPS, this means the disease is not the only thing working against them. A comprehensive care plan has to account for the whole picture, not just the stiffness and spasms.

Mental Health and the Quality-of-Life Dimension

Life expectancy is one measure, but for many people with SPS, the quality of the years they have weighs just as heavily. The first formal study of quality of life in SPS found that patients scored markedly lower than the general population across every dimension measured, including physical functioning, pain, social functioning, and mental health. Depression was common: more than half the participants showed depressive symptoms, and the severity of depression was closely linked to how much the disease had affected their overall functioning.²⁴

A particularly underappreciated consequence is phobia. In one study, about 44% of SPS patients developed task-specific phobias, meaning they became afraid of and began avoiding situations that were difficult because of their motor symptoms, such as crossing streets or navigating stairs. An additional 7% had phobic anxiety without full avoidance behavior.²⁵ These phobias are not irrational fears detached from reality. They arise directly from the experience of unpredictable spasms and falls, and they can progressively shrink a person’s world even when their physical symptoms are partially controlled. Recognizing and treating these psychological effects is as important to functional survival as managing the stiffness itself.